In July 2020, ReAlta announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for RLS-0071 for the treatment of acute lung injury secondary to COVID-19. ReAlta expects to begin enrolling in the 2nd quarter of 2021 a Phase 1 randomized, double-blind, placebo-controlled clinical trial of RLS-0071 in adult patients with pneumonia and early respiratory failure.
In parallel, ReAlta is exploring the ability of RLS-0071 to treat acute lung injury triggered by other viral infections such as RSV and influenza, and in other acute pulmonary disease processes.
Acute lung injury (ALI) associated with COVID-19 is the most frequent cause of death related to the infection, with limited benefit shown from current treatments.Learn More
Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.Learn More
A hemolytic transfusion reaction is a serious complication that can occur after a blood transfusion.Learn More
Autoimmune hemolytic anemia is a group of disorders characterized by a malfunction of the immune system that produces autoantibodies, which attack red blood cells as if they were substances foreign to the body.Learn More